Valeant Pharmaceuticals To Present At Financial Industry Conferences

May 31, 2017

LAVAL, Quebec, May 31, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that  Paul Herendeen, executive vice president and chief financial officer, and Linda LaGorga, senior vice president, finance and treasurer, are scheduled to present at the following financial industry conferences:

  • Barclays High Yield Bond & Syndicated Loan Conference on Friday, June 9, 2017 at 7:45 a.m. MDT (9:45 a.m. EDT) at The Broadmoor, Colorado Springs, Colo.; and
  • Goldman Sachs Second Annual Leveraged Finance Conference on Tuesday, June 20, 2017 at 10:40 a.m. PDT (1:40 p.m. EDT) at Terranea, Rancho Palos Verde, Calif.

A live webcast and audio archive of the events will be available on Valeant's Investor Relations website and via this URL:

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant and forward looking statements can be found at

Contact Information
Elif McDonald
877-281-6642 (toll free)

Lainie Keller

Valeant Pharmaceuticals International, Inc. (PRNewsFoto/Valeant Pharmaceuticals International, Inc.) (PRNewsFoto/)


To view the original version on PR Newswire, visit:

SOURCE Valeant Pharmaceuticals International, Inc.